Evidence map›Paper›PMID 32724385›Full record

ArticleOncology letters2020

IGF2BP3 and miR191-5p synergistically increase HCC cell invasiveness by altering ZO-1 expression.

Yuan Gao, Tianping Luo, Xiwu Ouyang, Chunfu Zhu, Junqiang Zhu, Xihu Qin

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. IGF2BPs as novel mGenes & diseases · 2024
    Review
  8. Review
  9. Landscape of mFrontiers in pharmacology · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. RNA mInnovation (Cambridge (Mass.)) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yuan GaoDepartment of General Surgery, No. 2 People's Hospital of Changzhou, Nanjing Medical University, Changzhou, Jiangsu 213100, P.R. China.
Tianping LuoDepartment of General Surgery, No. 2 People's Hospital of Changzhou, Nanjing Medical University, Changzhou, Jiangsu 213100, P.R. China.
Xiwu OuyangDepartment of Liver Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China.
Chunfu ZhuDepartment of General Surgery, No. 2 People's Hospital of Changzhou, Nanjing Medical University, Changzhou, Jiangsu 213100, P.R. China.
Junqiang ZhuDepartment of General Surgery, No. 2 People's Hospital of Changzhou, Nanjing Medical University, Changzhou, Jiangsu 213100, P.R. China.
Xihu QinDepartment of General Surgery, No. 2 People's Hospital of Changzhou, Nanjing Medical University, Changzhou, Jiangsu 213100, P.R. China.
Nanjing Medical University · CNChangzhou No.2 People's Hospital · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early studies have indicated that insulin-like growth factor II mRNA binding protein 3 (IGF2BP3/IMP3) may affect the progression of hepatocellular carcinoma (HCC); however, the detailed underlying mechanisms, particularly its linkage to tight junction protein-mediated cell invasion, remain unclear. The present study revealed that IGF2BP3 increased HCC cell invasiveness by suppressing zonula occludens-1 (ZO-1) expression, via direct binding to the 3' untranslated region (3'-UTR). Analysis of the molecular mechanisms demonstrated that IGF2BP3 binds to the overlapping targets of IGF2BP3-RNA cross-linkage and microRNA (miR)191-5p targeting sites, and promotes the formation of an miR191-5p-induced RNA-induced silencing complex. The knockdown of IGF2BP3 or the addition of a miR-191-5p inhibitor decreased cellular invasiveness and increased ZO-1 expression. Analysis of the human HCC database also confirmed the association between IGF2BP3 and HCC progression. Collectively, these preclinical findings suggest that IGF2BP3 increases HCC cell invasiveness by promoting the miR191-5p-induced suppression of ZO-1 signaling. This newly identified signaling effect on small molecule targeting may aid in the development of novel strategies with which to inhibit HCC progression more effectively.

Indexed as

cell invasionhepatocellular carcinomainsulin-like growth factor II mRNA binding protein 3microRNA-191-5pRNA binding proteintjp1zonula occludens-1

Identifiers

PMID32724385
PMCPMC7377053
OpenAlexW3032080444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.